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We report 5 HIV-infected Ugandan adults with cryptococcal 
and tuberculous (TB) meningitis co-infection. All unmasked 
meningitis occurred within 5 weeks of starting HIV therapy. 
Xpert MTB/RIF Ultra facilitated prompt diagnosis; however, 
60% in-hospital mortality occurred. TB meningitis coinfection 
prevalence was 0.8% (5/586) among cryptococcal meningitis, 2 
during second cryptococcal episodes.
Keywords. case series; cryptococcal meningitis; HIV/
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Meningitis remains a major cause of mortality in Africa and is 
the medical condition associated with highest risk of inpatient 
death [1]. Cryptococcal meningitis (CM) is the most common 
causative pathogen in advanced HIV; in 2014, there were an 
estimated 250 000 incident cases of cryptococcosis, accounting 
for 15% of AIDS-related deaths [2]. Tuberculous meningitis 
(TBM) is the second most common cause of HIV-associated 
meningitis [3]. Duel co-infection is rarely described.
In a systematic review of TB/cryptococcosis infection in 
China, Fang et al. identified 197 cases of co-infection, of whom 
19% (n = 37) were in HIV-infected patients. TBM/CM was the 
most frequent co-infection (54%, 94/174) [4]. CM/TBM co-in-
fection has been described in case reports in patients with a 
range of underlying immunodeficiencies, including HIV (n = 3) 
[5–7], systemic lupus erythematosus (n  =  1), Waldenstrom’s 
macroglobulinemia (n = 1), and reticulum cell sarcoma (n = 1), 
and in patients with no underlying immunodeficiency (n = 2) 
[8]. Here we present a case series of 5 Ugandan adults with HIV-
associated CM/TBM co-infection.
METHODS
Five cases of CM/TBM co-infection were observed in the 
ASTRO-CM trial, a phase III, placebo-controlled, randomized 
clinical trial to evaluate whether sertraline, when added to stand-
ard amphotericin-based therapy for cryptococcal meningitis, 
leads to improved survival (ClinicalTrials.gov: NCT01802385) 
[9]. The primary outcome was 18-week survival. HIV-infected 
adults (age ≥18 years) presenting with CM to Mulago National 
Referral Hospital, Kampala, or Mbarara Regional Referral 
Hospital received standard amphotericin-based induction ther-
apy and were randomized to receive either sertraline (400 mg/d) 
or placebo. CM was diagnosed by cerebrospinal fluid (CSF) 
using cryptococcal antigen lateral flow assay (CrAg LFA, IMMY, 
Norman, OK). Makerere Microbiology Laboratory performed 
CSF testing of white cell count, protein, and quantitative crypto-
coccal cultures. CSF glucose testing was mostly unavailable.
Participants were not routinely screened for CM/TBM co-in-
fection; however, when concurrent TBM infection was suspected, 
participants were evaluated for TB at the physician’s discretion. 
CSF testing for TBM was as follows: CSF Acid Fast Bacilli smear 
using Ziehl-Neelsen stain (Mulago Hospital only), Xpert MTB/Rif 
(2013–2016) and/or Xpert MTB/Rif Ultra testing (2017; Cepheid, 
Sunnyvale, CA), and/or for CSF Mycobacteria Growth Inhibitor 
Tube culture (MGIT, Becton Dickinson, Franklin Lakes, NJ). 
A diagnosis of CM/TBM co-infection was established in patients 
with microbiologically confirmed CM via a positive CSF CrAg and 
TBM via positive CSF Xpert MTB/Rif or MGIT culture. The cases 
were classified as (i) concurrent co-infection, indicating that the 2 
infections were diagnosed simultaneously, or (ii) sequential co-in-
fection when TBM was diagnosed during recurrent meningitis.
The ASTRO-CM trial protocol was approved by Ugandan and 
Minnesotan institutional review boards. All participants (or sur-
rogates in cases of incapacity) provided written informed consent.
Case Presentations
From March 2015 until September 2017, 586 HIV-infected adults 
were diagnosed with cryptococcal meningitis among 839 con-
sented participants with suspected meningitis. A total of 5 cases 
of CM/TBM co-infection were diagnosed (Table 1). All cases were 
confirmed TBM: 4 by Xpert MTB/RIF Ultra and 1 by culture.
The median age (range) was 32 (26–40) years, and 80% were 
male (4/5). All participants had advanced HIV/AIDS with a 
median CD4 (range) of 10 (1–79) cells/μL and a median hemo-
globin of 12.2 (8.2–18.7) g/dL. All 5 were on antiretroviral 
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therapy (ART) at hospital presentation. The median duration 
on ART at recruitment  was (range)  13 (11–35) days. Two 
patients had no prior TB history or therapy. One patient (case 
3) was on antituberculous therapy, and 2 patients (cases 1 and 
4) had a previous history of treated TB infection.
Participants presented with features typical of subacute men-
ingitis: all patients reported headache, with a median duration 
(range) of 30 (7–30) days; 60% (3/5) reported fever, 40% (2/5) 
reported seizures, and 20% (1/5) reported visual disturbance or 
photophobia, respectively. The median Glasgow Coma Score 
(GCS) was (range) 12 (6–15), and 40% (2/5) of patients had a 
sixth cranial nerve palsy on examination. CSF opening pres-
sure at diagnosis was raised (>20  cmH20) in 40% (2/5), with 
a median opening pressure of (range)  16 (5–46) cmH20. The 
baseline median CSF white cell count (range) was 60 (<5–2200) 
cells/µL, and median protein was 100 (20–356) mg/dL. Two 
patients (40%) had sterile CSF cryptococcal cultures with posi-
tive serum and CSF CrAg tests.
TBM was diagnosed concurrently in 3 cases and sequentially 
in 2 cases (cases 1 and 2). Case 1 had a previous history of CM, 
completing treatment 12  years earlier, and presented on this 
occasion 1 month after restarting ART with a 1-month history 
of meningitis symptoms. At recruitment, the CD4 was 10 cells/
μL, CSF CrAg LFA was faintly positive, CSF white cells <5 cells/
µL, and CSF protein 20 mg/dL. Antifungal treatment was started 
for possible cryptococcal relapse, although CSF fungal cultures 
remained sterile. A second lumbar puncture on day 3 of anti-
fungal therapy revealed a CSF white cell count of 165 cells/μL 
(100% lymphocytes), with protein of 74 mg/dL. The participant 
died on day +10 before mycobacterial cultures grew on day +11. 
Case 2 presented to the hospital 173 days after his initial crypto-
coccal diagnosis with recurrence of meningitis symptoms and 
was diagnosed with TBM promptly by Xpert Ultra.
The in-hospital mortality was 60% (3/5). One patient was 
alive at 18-week follow-up. Three patients died 2–11 days after 
diagnosis. The fifth patient survived to hospital discharge, but 
they were not actively followed thereafter. Four CM/TBM diag-
noses were made after January 2017, when Xpert MTB/RIF 
Ultra testing was introduced. Before this time, 0.2% (1/453) 
with confirmed CM were diagnosed with concurrent TBM, 
compared with 3% (4/133) in the post–Xpert MTB/RIF Ultra 
period (P = .011).
DISCUSSION
While CM/TB co-infection has been previously described 
[10, 11], CM/TBM co-infection is reported to be extremely 
rare. The diagnosis of CM/TBM co-infection is particularly 
challenging due to the paucibacillary nature of TBM. As such, 
data on HIV-associated CM/TBM co-infection are limited to 
individual case reports [5–7]. The introduction of Xpert MTB/
Rif, which is a cartridge-based, fully automated polymerase 
chain reaction molecular assay, was a step forward. However, 
the introduction in 2016 of the re-engineered Xpert MTB/RIF 
Ultra has significantly improved our TBM diagnostic capacity. 
In the context of these new diagnostics, we report a case series 
of 5 HIV-associated CM/TBM co-infection cases.
In our cohort of severely immunocompromised HIV-
infected adults with cryptococcosis, where TBM was selectively 
screened for, CM/TBM coinfection occurred in 0.5% (3/586) 
of first episodes of cryptococcosis and 0.8% (5/586) overall, 
with 2 sequential TBM infections being recurrent meningi-
tis episodes. Our Ugandan prevalence is lower than the 1.5% 
CM/TBM co-infection rate reported among HIV-associated 
CM patients (8/514) in South Africa, where the TB incidence 
is ~5-fold higher [12]. A single-center case series from Taiwan 
[11] reported 23 cases of cryptococcosis/TB co-infection at any 
Table 1. Clinical Characteristics of 5 Cases of HIV-Associated Cryptococcal Meningitis and Tuberculous Meningitis Co-infection
Case Age Sex
Days on 
ART CD4 Cells/μL
History of 
CM
History 
of TB
Days From 
CM to TBM 
Diagnosis CSF TB Diagnostics
CSF White 
Cells/μL
CSF Protein, 
mg/dL
Cryptococcus CFU/ 
mL CSF Outcome
1 40 F 30 10 12 y prior Y 11 Xpert MTB/RIF (-)
MGIT culture (+)
<5
155a
20
74a
0
0a
Death, day 10
2 35 M 13
186b
79 N N 173 Xpert Ultra (+)
MGIT culture  
not done
115
2200b
157
356b
12 300
0b
Alive at 
discharge
3 26 M 35 19 N N 0 Xpert Ultra (+)
MGIT culture (-)
205 100 0 Death, day 11
4 32 M 11 1 N Y 0 Xpert Ultra (+)
MGIT culture 
contaminated
210 40 520 000 Death, day 2
5 32 M 5 3 N N 0 Xpert Ultra (+)
MGIT culture  
not done
<5 N/A 20 000 Alive >18 wk
Abbreviations: ART, antiretroviral therapy; CFU, colony-forming units; CM, cryptococcal meningitis; CSF, cerebrospinal fluid; MGIT, mycobacteria growth indicator tube; TB, tuberculosis; TBM, 
tuberculous meningitis.
aDay 3 lumbar puncture.
bAt the time of TBM diagnosis.
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site (11/23, 48% in HIV-infected patients), representing 5.4% of 
cryptococcosis cases.
The marked overlap in clinical presentation between CM and 
TBM may lead to delayed or missed diagnoses. Indeed, the clin-
ical presentations and CSF profiles observed in our CM/TBM 
co-infection cohort are comparable to those described in HIV-
associated CM or TBM mono-infection. The high early mor-
tality rate associated with CM may also mean that CM patients 
die before a diagnosis of concurrent TBM is made, which may 
also result in underdiagnosis of co-infection. To date, there are 
no discriminatory biomarkers that can distinguish co-infection 
from CM or TBM mono-infection.
CM/TBM co-infection reflects the advanced immunosup-
pression characteristic of patients with HIV-associated CM and 
the complexities of diagnosis and management in patients who 
remain at risk of intercurrent opportunistic infections. This case 
series demonstrates both the need to consider co-infection at 
baseline diagnosis and the need to remain vigilant for co-infec-
tion throughout the follow-up period.
Each case of CM/TBM co-infection occurred in patients who 
had recently started on ART (median time on ART, 13 days). 
This contrasts with the 44% (202/460) of the overall ASTRO 
cohort who were receiving ART at recruitment. Although our 
numbers are small, this may suggest that patients presenting 
with CNS infection soon after ART initiation, a clinical phe-
notype consistent with unmasking immune reconstitution 
inflammatory syndrome (IRIS), may be at particularly high 
risk of CM/TBM co-infection. As demonstrated by cases 1–2, 
considering TBM is important in patients presenting with sus-
pected CM relapse following ART initiation. IRIS is caused 
by recovery of pathogen-specific immune responses follow-
ing ART initiation that result in a pathological inflammatory 
response. In unmasking CM-IRIS, this manifests as a patient 
with previously undiagnosed cryptococcosis presenting with 
meningitis soon after ART is started. In unmasking TBM-IRIS, 
dormant Rich foci on the meninges become inflamed due to 
TB-specific immune responses, resulting in rupture and trans-
location of bacilli into the subarachnoid space, with associated 
inflammatory meningitis. Pathogen-specific immune responses 
may recover simultaneously or sequentially, resulting in IRIS 
phenomena to several pathogens and therein the presentation 
of co-infections.
In conclusion, CM/TBM co-infection in HIV-infected adults 
remains a rare condition, but one of which physicians should 
remain aware. The introduction of molecular tests like Xpert 
MTB/Rif Ultra has improved our capacity to diagnose TBM; 
whether patients presenting with CM unmasking IRIS are at 
higher risk of CM/TBM co-infection and whether co-infection 
is associated with increased mortality warrant further investiga-
tion. Providers should be aware that the recent rapid upscaling 
of “HIV test and treat” could result in an increased incidence of 
co-infection unmasking IRIS events.
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